Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Cash from Financing Activities (2020 - 2025)

SAB Biotherapeutics' Cash from Financing Activities history spans 6 years, with the latest figure at -$41685.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 119.21% year-over-year to -$41685.0; the TTM value through Dec 2025 reached $168.3 million, up 14452.36%, while the annual FY2025 figure was $168.3 million, 14452.36% up from the prior year.
  • Cash from Financing Activities reached -$41685.0 in Q4 2025 per SABSW's latest filing, down from $168.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $168.7 million in Q3 2025 to a low of -$6.3 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $13.5 million, with a median of -$157076.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 37883.67% in 2021, then plummeted 13794.46% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $36.0 million in 2021, then plummeted by 76.72% to $8.4 million in 2022, then soared by 706.4% to $67.6 million in 2023, then tumbled by 99.68% to $216961.0 in 2024, then tumbled by 119.21% to -$41685.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Cash from Financing Activities are -$41685.0 (Q4 2025), $168.7 million (Q3 2025), and -$173844.0 (Q2 2025).